查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679414

医药市场规模、份额和趋势分析报告：按分子类型、产品类型、疾病、年龄层、给药途径、分销管道、地区、细分趋势，2025-2030 年

Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 250 Pages | 商品交期: 2-10个工作天内

价格

医药市场的成长与趋势

根据Grand View Research, Inc.的最新报告，到2030年全球医药市场规模预计将达到23,504.3亿美元，预计2025年至2030年的复合年增长率为6.12%。

医药市场的成长是由慢性病日益流行的推动的，这推动了开发新型治疗方法的需求。根据美国国家老龄委员会估计，大约 95% 的老年人患有至少一种慢性病，大约 80% 的老年人患有两种或两种以上的慢性病。此外，糖尿病、关节炎和心臟病等慢性疾病对老年人的影响尤其严重。

意识是预防、早期发现、有针对性的照护和有效治疗的关键。了解疾病及其症状的人更有可能采取预防措施，如筛检、测试和身体检查。人们对各种疾病的认识不断提高也是製药业发展的驱动因素之一。现在人们对癌症和糖尿病等疾病的认识有所提高，一旦患上这些疾病，他们就更有可能寻求治疗。公共和私人组织正在采取各种措施来传播意识并教育公众。此外，越来越多的人购买保险来支付处方药费用，增加了药品需求。

此外，新疗法开发技术的进步导致全球对药品的需求大幅增加。製药业在研发以及产品销售和分销方面的投资比以往任何时候都多。这个行业专注于明确和直接地解决人们的健康问题。製药业对患者护理和社区发展至关重要，提供无数挽救生命的治疗，创造就业机会并为全球经济做出贡献。

许多生技药品，包括细菌和病毒，都用于疫苗生产、发酵过程和生物技术。该市场由各种各样的公司组成，包括大型製药公司、中型专业製药公司、虚拟製药公司、非专利製造商以及小型生物技术和生物製药公司。此外，参与开发和配製各种治疗製剂的主要参与企业正在加强合作和伙伴关係，以开发新药并保持市场竞争力。

此外，一些公司正在致力于开发新药，以满足日益增长的预防和治疗该疾病的需求。例如，2023年4月，罗氏公司宣布，其治疗湿性老龄化黄斑部病变的药物Vabysmo（该药物于2022年1月获得FDA核准）在2023年第一季的销售额约为5亿美元，同比增长超过500%，超过了多发性硬化症治疗药物Ocrevus和血友病药物。此外，2023年7月，诺华公司获得美国FDA批准，扩大Rekmeo（通用名：inclisiran）的核准，包括治疗高LDL-C水平且患有心臟病风险高的患者。

医药市场报告重点

  • 到 2024 年，传统药物（小分子）将占据市场主导地位，销售额占 54.74%。
  • 品牌药将主导医药市场，到 2024 年销售额将占 86.76%。
  • 由于慢性病治疗需求的不断增长、药物开发技术的进步以及医疗保健管道的改善，处方笺部分在 2024 年占据了市场主导地位，收入份额达到 86.76%。
  • 2024 年，肿瘤学领域占据市场主导地位，收入份额为 18.06%。
  • 口服製剂领域占据胜肽药物结合物市场的主导地位，由于其便利性、患者依从性和成本效益，2024 年的收益占有率为 57.53%。
  • 在胜肽药物偶联物市场中，成人市场在 2024 年占据 63.84% 的收入份额。
  • 医院药局部门在胜肽结合物市场占据主导地位，2024 年的收入份额为 53.53%。

目录

第一章调查方法与范围

第二章执行摘要

第三章医药市场变数、趋势和范围

  • 母市场展望
  • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 多巴胺促效剂分析工具
    • 波特的分析
    • PESTEL分析
  • 管道分析
    • 第一阶段
    • 第 2 阶段
    • 第 3 阶段

第四章：医药市场：依药物的估计与趋势分析

  • 医药市场：药品细分仪表板
  • 医药市场：药物趋势分析（百万美元），2024 年与 2030 年
  • 生技药品和生物相似药（聚合物）
    • 单株抗体
    • 疫苗
    • 细胞和基因治疗
    • 其他的
  • 常规药物（小分子）

第五章：医药市场类型、估价与趋势分析

  • 医药市场：型细分仪表板
  • 医药市场：类型变化分析，百万美元，2024 年与 2030 年
  • 处方药
  • 非处方药

第六章：医药市场：产品特定、估计与趋势分析

  • 医药市场：产品细分仪表板
  • 医药市场：产品差异分析，百万美元，2024 年对比 2030 年
  • 品牌
  • 非专利的

第七章：医药市场：特定疾病、估计与趋势分析

  • 医药市场：疾病细分仪表板
  • 医药市场：疾病趋势分析（百万美元），2024 年和 2030 年
  • 心血管疾病
  • 癌症
  • 糖尿病
  • 感染疾病
  • 神经系统疾病
  • 呼吸系统疾病
  • 自体免疫疾病
  • 精神疾病
  • 胃肠道疾病
  • 女性健康疾病
  • 遗传疾病及罕见遗传疾病
  • 皮肤病
  • 肥胖
  • 肾臟疾病
  • 肝臟疾病
  • 血液系统疾病
  • 眼部疾病
  • 不孕不育
  • 内分泌失调
  • 过敏
  • 其他的

第 8 章：按给药途径分類的药品市场、估计和趋势分析

  • 医药市场：细分仪表板
  • 医药市场：给药途径变化分析，百万美元，2024 年与 2030 年
  • 口服
    • 锭剂
    • 胶囊
    • 暂停
    • 其他的
  • 局部的
  • 肠外
    • 静脉
    • 肌肉注射
  • 吸入
  • 其他的

第九章：医药市场：依年龄组别估计和趋势分析

  • 医药市场：年龄层细分仪表板
  • 医药市场：年龄人口统计分析，百万美元，2024 年和 2030 年
  • 儿童和青少年
  • 成人
  • 老年人

第 10 章：医药市场：按分销管道分類的估计和趋势分析

  • 医药市场：通路细分仪表板
  • 医药市场：通路变化分析（百万美元），2024 年比较 2030 年
  • 医院药房
  • 零售药局
  • 其他的

第 11 章医药市场：区域、估计与趋势分析

  • 2024 年及 2030 年各地区医药市场占有率（百万美元）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十二章竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 参与者概述
  • 产品基准
  • 2024年公司市场占有率分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GlaxoSmithKline plc.
    • AstraZeneca
    • Takeda Pharmaceutical Co., Ltd.

第十三章 结论

Product Code: GVR-4-68040-159-7

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is estimated to reach USD 2,350.43 billion by 2030, registering to grow at a CAGR of 6.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

  • The Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
  • The branded segment dominated the pharmaceutical market with a revenue share of 86.76% in 2024.
  • The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access.
  • The cancer segment dominated the market with a revenue share of 18.06% in 2024.
  • The oral segment dominated the peptide drug conjugates market with a revenue share of 57.53% in 2024 due to its convenience, patient compliance, and cost-effectiveness.
  • The adults segment dominated the peptide drug conjugates market with a revenue share of 63.84% in 2024.
  • The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Advancement in therapeutics and robust product pipeline
      • 3.3.1.2. Rise in pharmaceutical r&d spending
      • 3.3.1.3. Rise in pharmaceutical r&d spending
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Patent expiration of key market drugs
      • 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
      • 3.3.2.3. Stringent regulatory scenario
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Pharmaceutical Market: By Drug Estimates & Trend Analysis

  • 4.1. Pharmaceutical Market: Drug Segment Dashboard
  • 4.2. Pharmaceutical Market: By Drug Movement Analysis, USD Million, 2024 & 2030
  • 4.3. Biologics & Biosimilars (Large Molecules)
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Monoclonal Antibodies
      • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Vaccines
      • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Cell & Gene Therapy
      • 4.3.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Conventional Drugs (Small Molecules)
    • 4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 5.1. Pharmaceutical Market: Type Segment Dashboard
  • 5.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
  • 5.3. Prescription
    • 5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. OTC
    • 5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 6.1. Pharmaceutical Market: Product Segment Dashboard
  • 6.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
  • 6.3. Branded
    • 6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Generics
    • 6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis

  • 7.1. Pharmaceutical Market: Disease Segment Dashboard
  • 7.2. Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
  • 7.3. Cardiovascular diseases
    • 7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Cancer
    • 7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Diabetes
    • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Infectious diseases
    • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Neurological disorders
    • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Respiratory diseases
    • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Autoimmune diseases
    • 7.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Mental health disorders
    • 7.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11. Gastrointestinal disorders
    • 7.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.12. Women's Health Diseases
    • 7.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.13. Genetic and Rare genetic diseases
    • 7.13.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.14. Dermatological conditions
    • 7.14.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.15. Obesity
    • 7.15.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.16. Renal diseases
    • 7.16.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.17. Liver conditions
    • 7.17.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.18. Hematological disorders
    • 7.18.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.19. Eye conditions
    • 7.19.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.20. Infertility conditions
    • 7.20.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.21. Endocrine disorders
    • 7.21.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.22. Allergies
    • 7.22.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.23. Others
    • 7.23.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
  • 8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
  • 8.3. Oral
    • 8.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Tablets
    • 8.3.3. Capsules
    • 8.3.4. Suspensions
    • 8.3.5. Other
  • 8.4. Topical
    • 8.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Parenteral
    • 8.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Intravenous
    • 8.5.3. Intramuscular
  • 8.6. Inhalations
    • 8.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Other Routes of Administration
    • 8.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. Pharmaceutical Market: Age Group Segment Dashboard
  • 9.2. Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
  • 9.3. Children & Adolescents
    • 9.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Adults
    • 9.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Geriatric
    • 9.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis

  • 10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
  • 10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
  • 10.3. Hospital Pharmacy
    • 10.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4. Retail Pharmacy
    • 10.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5. Others
    • 10.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Pharmaceutical Market: Regional Estimates & Trend Analysis

  • 11.1. Pharmaceutical Market Share, By Region, 2024 & 2030, USD Million
  • 11.2. North America
    • 11.2.1. North America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.2. U.S.
      • 11.2.2.1. Key Country Dynamics
      • 11.2.2.2. Target Disease Prevalence
      • 11.2.2.3. Regulatory Framework
      • 11.2.2.4. Reimbursement Framework
      • 11.2.2.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.3. Canada
      • 11.2.3.1. Key Country Dynamics
      • 11.2.3.2. Target Disease Prevalence
      • 11.2.3.3. Regulatory Framework
      • 11.2.3.4. Reimbursement Framework
      • 11.2.3.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.4. Mexico
      • 11.2.4.1. Key Country Dynamics
      • 11.2.4.2. Target Disease Prevalence
      • 11.2.4.3. Regulatory Framework
      • 11.2.4.4. Reimbursement Framework
      • 11.2.4.5. Mexico Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3. Europe
    • 11.3.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.2. UK
      • 11.3.2.1. Key Country Dynamics
      • 11.3.2.2. Target Disease Prevalence
      • 11.3.2.3. Regulatory Framework
      • 11.3.2.4. Reimbursement Framework
      • 11.3.2.5. Uk Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.3. Germany
      • 11.3.3.1. Key Country Dynamics
      • 11.3.3.2. Target Disease Prevalence
      • 11.3.3.3. Regulatory Framework
      • 11.3.3.4. Reimbursement Framework
      • 11.3.3.5. Germany Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.4. France
      • 11.3.4.1. Key Country Dynamics
      • 11.3.4.2. Target Disease Prevalence
      • 11.3.4.3. Regulatory Framework
      • 11.3.4.4. Reimbursement Framework
      • 11.3.4.5. France Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.5. Italy
      • 11.3.5.1. Key Country Dynamics
      • 11.3.5.2. Target Disease Prevalence
      • 11.3.5.3. Regulatory Framework
      • 11.3.5.4. Reimbursement Framework
      • 11.3.5.5. Italy Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.6. Spain
      • 11.3.6.1. Key Country Dynamics
      • 11.3.6.2. Target Disease Prevalence
      • 11.3.6.3. Regulatory Framework
      • 11.3.6.4. Reimbursement Framework
      • 11.3.6.5. Spain Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.7. Denmark
      • 11.3.7.1. Key Country Dynamics
      • 11.3.7.2. Target Disease Prevalence
      • 11.3.7.3. Regulatory Framework
      • 11.3.7.4. Reimbursement Framework
      • 11.3.7.5. Denmark Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.8. Sweden
      • 11.3.8.1. Key Country Dynamics
      • 11.3.8.2. Target Disease Prevalence
      • 11.3.8.3. Regulatory Framework
      • 11.3.8.4. Reimbursement Framework
      • 11.3.8.5. Sweden Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.9. Norway
      • 11.3.9.1. Key Country Dynamics
      • 11.3.9.2. Target Disease Prevalence
      • 11.3.9.3. Regulatory Framework
      • 11.3.9.4. Reimbursement Framework
      • 11.3.9.5. Norway Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4. Asia Pacific
    • 11.4.1. Asia Pacific Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.2. Japan
      • 11.4.2.1. Key Country Dynamics
      • 11.4.2.2. Target Disease Prevalence
      • 11.4.2.3. Regulatory Framework
      • 11.4.2.4. Reimbursement Framework
      • 11.4.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.3. China
      • 11.4.3.1. Key Country Dynamics
      • 11.4.3.2. Target Disease Prevalence
      • 11.4.3.3. Regulatory Framework
      • 11.4.3.4. Reimbursement Framework
      • 11.4.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.4. India
      • 11.4.4.1. Key Country Dynamics
      • 11.4.4.2. Target Disease Prevalence
      • 11.4.4.3. Regulatory Framework
      • 11.4.4.4. Reimbursement Framework
      • 11.4.4.5. India Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.5. Australia
      • 11.4.5.1. Key Country Dynamics
      • 11.4.5.2. Target Disease Prevalence
      • 11.4.5.3. Regulatory Framework
      • 11.4.5.4. Reimbursement Framework
      • 11.4.5.5. Australia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.6. South Korea
      • 11.4.6.1. Key Country Dynamics
      • 11.4.6.2. Target Disease Prevalence
      • 11.4.6.3. Regulatory Framework
      • 11.4.6.4. Reimbursement Framework
      • 11.4.6.5. South Korea Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.7. Thailand
      • 11.4.7.1. Key Country Dynamics
      • 11.4.7.2. Target Disease Prevalence
      • 11.4.7.3. Regulatory Framework
      • 11.4.7.4. Reimbursement Framework
      • 11.4.7.5. Thailand Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5. Latin America
    • 11.5.1. Latin America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.5.2. Brazil
      • 11.5.2.1. Key Country Dynamics
      • 11.5.2.2. Target Disease Prevalence
      • 11.5.2.3. Regulatory Framework
      • 11.5.2.4. Reimbursement Framework
      • 11.5.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.5.3. Argentina
      • 11.5.3.1. Key Country Dynamics
      • 11.5.3.2. Target Disease Prevalence
      • 11.5.3.3. Regulatory Framework
      • 11.5.3.4. Reimbursement Framework
      • 11.5.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Middle East and Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.2. South Africa
      • 11.6.2.1. Key Country Dynamics
      • 11.6.2.2. Target Disease Prevalence
      • 11.6.2.3. Regulatory Framework
      • 11.6.2.4. Reimbursement Framework
      • 11.6.2.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.3. Saudi Arabia
      • 11.6.3.1. Key Country Dynamics
      • 11.6.3.2. Target Disease Prevalence
      • 11.6.3.3. Regulatory Framework
      • 11.6.3.4. Reimbursement Framework
      • 11.6.3.5. Saudi Arabia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.4. UAE
      • 11.6.4.1. Key Country Dynamics
      • 11.6.4.2. Target Disease Prevalence
      • 11.6.4.3. Regulatory Framework
      • 11.6.4.4. Reimbursement Framework
      • 11.6.4.5. UAE Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.5. Kuwait
      • 11.6.5.1. Key Country Dynamics
      • 11.6.5.2. Target Disease Prevalence
      • 11.6.5.3. Regulatory Framework
      • 11.6.5.4. Reimbursement Framework
      • 11.6.5.5. Kuwait Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

  • 12.1. Recent Developments & Impact Analysis by Key Market Participants
  • 12.2. Company Categorization
  • 12.3. Participant Overview
  • 12.4. Financial Performance
  • 12.5. Product Bench Marking
  • 12.6. Company Market Share Analysis, 2024
  • 12.7. Company Profiles
    • 12.7.1. F. Hoffmann-La Roche Ltd
      • 12.7.1.1. Participant's Overview
      • 12.7.1.2. Financial Performance
      • 12.7.1.3. Product Benchmarking
      • 12.7.1.4. Recent Developments/ Strategic Initiatives
    • 12.7.2. Novartis AG
      • 12.7.2.1. Participant's Overview
      • 12.7.2.2. Financial Performance
      • 12.7.2.3. Product Benchmarking
      • 12.7.2.4. Recent Developments/ Strategic Initiatives
    • 12.7.3. AbbVie Inc.
      • 12.7.3.1. Participant's Overview
      • 12.7.3.2. Financial Performance
      • 12.7.3.3. Product Benchmarking
      • 12.7.3.4. Recent Developments/ Strategic Initiatives
    • 12.7.4. Johnson & Johnson Services, Inc.
      • 12.7.4.1. Participant's Overview
      • 12.7.4.2. Financial Performance
      • 12.7.4.3. Product Benchmarking
      • 12.7.4.4. Recent Developments/ Strategic Initiatives
    • 12.7.5. Merck & Co., Inc.
      • 12.7.5.1. Participant's Overview
      • 12.7.5.2. Financial Performance
      • 12.7.5.3. Product Benchmarking
      • 12.7.5.4. Recent Developments/ Strategic Initiatives
    • 12.7.6. Pfizer Inc.
      • 12.7.6.1. Participant's Overview
      • 12.7.6.2. Financial Performance
      • 12.7.6.3. Product Benchmarking
      • 12.7.6.4. Recent Developments/ Strategic Initiatives
    • 12.7.7. Bristol-Myers Squibb Company
      • 12.7.7.1. Participant's Overview
      • 12.7.7.2. Financial Performance
      • 12.7.7.3. Product Benchmarking
      • 12.7.7.4. Recent Developments/ Strategic Initiatives
    • 12.7.8. Sanofi
      • 12.7.8.1. Participant's Overview
      • 12.7.8.2. Financial Performance
      • 12.7.8.3. Product Benchmarking
      • 12.7.8.4. Recent Developments/ Strategic Initiatives
    • 12.7.9. GlaxoSmithKline plc.
      • 12.7.9.1. Participant's Overview
      • 12.7.9.2. Financial Performance
      • 12.7.9.3. Product Benchmarking
      • 12.7.9.4. Recent Developments/ Strategic Initiatives
    • 12.7.10. AstraZeneca
      • 12.7.10.1. Participant's Overview
      • 12.7.10.2. Financial Performance
      • 12.7.10.3. Product Benchmarking
      • 12.7.10.4. Recent Developments/ Strategic Initiatives
    • 12.7.11. Takeda Pharmaceutical Co., Ltd.
      • 12.7.11.1. Participant's Overview
      • 12.7.11.2. Financial Performance
      • 12.7.11.3. Product Benchmarking
      • 12.7.11.4. Recent Developments/ Strategic Initiatives

Chapter 13. Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 Global Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 Global Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 Global Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 7 Global Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 Global Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 9 Global Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 10 North America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 11 North America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 12 North America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 13 North America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 14 North America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 15 North America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 16 North America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 17 North America Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 18 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 24 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Canada Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 26 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 27 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 28 Canada Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 29 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 30 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 31 Canada Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32 Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 33 Europe Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 34 Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 35 Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 36 Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 37 Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 38 Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 39 Europe Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 40 Germany Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 41 Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 42 Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 44 Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 45 Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 46 Germany Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 UK Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 48 UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 49 UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 50 UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 51 UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 52 UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 53 UK Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 54 France Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 55 France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 57 France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 58 France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 59 France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 60 France Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 61 Italy Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 62 Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 63 Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 64 Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 65 Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 67 Italy Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 68 Spain Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 69 Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 70 Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 71 Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 72 Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 73 Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 74 Spain Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 77 Asia Pacific Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 78 Asia Pacific Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 79 Asia Pacific Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 80 Asia Pacific Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Asia Pacific Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 82 Asia Pacific Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 83 China Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 84 China Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 China Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 86 China Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 87 China Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 88 China Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 89 China Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 90 Japan Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 91 Japan Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 92 Japan Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 93 Japan Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 94 Japan Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 95 Japan Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 96 Japan Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 India Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 98 India Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 99 India Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 100 India Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 101 India Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 102 India Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 103 India Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 104 Middle East Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 107 Middle East Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 108 Middle East Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 109 Middle East Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 110 Middle East Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 111 Middle East Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 112 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 117 Saudi Arabia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 118 Saudi Arabia Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 119 UAE Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 120 UAE Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 121 UAE Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 122 UAE Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 123 UAE Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 124 UAE Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 125 UAE Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 126 Kuwait Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 127 Kuwait Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 128 Kuwait Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 129 Kuwait Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 130 Kuwait Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 Kuwait Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 132 Kuwait Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Pharmaceutical Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Pharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 15 Pharmaceutical market: Molecule type movement analysis & market share 2024 & 2030
  • Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 17 Monoclonal Antibodies market, 2018 - 2030 (USD Billion)
  • Fig. 18 Vaccines market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell & Gene Therapy market, 2018 - 2030 (USD Billion)
  • Fig. 20 Others market, 2018 - 2030 (USD Billion)
  • Fig. 21 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 22 Pharmaceutical market: Product outlook and key takeaways
  • Fig. 23 Pharmaceutical market: Product movement analysis & market share 2024 & 2030
  • Fig. 24 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 25 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 26 Pharmaceutical market: Type outlook and key takeaways
  • Fig. 27 Pharmaceutical market: Type movement analysis & market share 2024 & 2030
  • Fig. 28 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 29 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 30 Pharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
  • Fig. 32 Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 33 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
  • Fig. 34 Diabetes market, 2018 - 2030 (USD Billion)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 36 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 37 Respiratory diseases market, 2018 - 2030 (USD Billion)
  • Fig. 38 Autoimmune diseases market, 2018 - 2030 (USD Billion)
  • Fig. 39 Mental health disorders market, 2018 - 2030 (USD Billion)
  • Fig. 40 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 41 Women's health diseases market, 2018 - 2030 (USD Billion)
  • Fig. 42 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 43 Dermatological conditions market, 2018 - 2030 (USD Billion)
  • Fig. 44 Obesity market, 2018 - 2030 (USD Billion)
  • Fig. 45 Renal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 46 Liver conditions market, 2018 - 2030 (USD Billion)
  • Fig. 47 Hemotological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 48 Eye conditions market, 2018 - 2030 (USD Billion)
  • Fig. 49 Infertility conditions market, 2018 - 2030 (USD Billion)
  • Fig. 50 Endocrine disorders market, 2018 - 2030 (USD Billion)
  • Fig. 51 Allergies market, 2018 - 2030 (USD Billion)
  • Fig. 52 Other diseases market, 2018 - 2030 (USD Billion)
  • Fig. 53 Pharmaceutical market: Route of administration outlook and key takeaways
  • Fig. 54 Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2030
  • Fig. 55 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 56 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 57 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 58 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 59 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 60 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 61 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 62 Intravenous market, 2018 - 2030 (USD Billion)
  • Fig. 63 Intramuscular market, 2018 - 2030 (USD Billion)
  • Fig. 64 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 65 Others pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 66 Pharmaceutical market: Age group outlook and key takeaways
  • Fig. 67 Pharmaceutical market: Age group movement analysis & market share 2024 & 2030
  • Fig. 68 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 69 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 70 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 71 Pharmaceutical market: Distribution Channel outlook and key takeaways
  • Fig. 72 Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2030
  • Fig. 73 Hospital Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 74 Retail Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 75 Others pharmaceutical market, 2018 - 2030 (USD Billion
  • Fig. 76 Regional Outlook, 2024 & 2030
  • Fig. 77 Regional Market Dashboard
  • Fig. 78 Regional Market Place: Key Takeaways
  • Fig. 79 North America
  • Fig. 80 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 U.S. Key Country Dynamics
  • Fig. 82 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Canada Key Country Dynamics
  • Fig. 84 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 Mexico Key Country Dynamics
  • Fig. 86 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Europe
  • Fig. 88 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 UK Key Country Dynamics
  • Fig. 90 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Germany Key Country Dynamics
  • Fig. 92 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 France Key Country Dynamics
  • Fig. 94 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Italy Key Country Dynamics
  • Fig. 96 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Spain Key Country Dynamics
  • Fig. 98 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 Denmark Key Country Dynamics
  • Fig. 100 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Sweden Key Country Dynamics
  • Fig. 102 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 Norway Key Country Dynamics
  • Fig. 104 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Asia Pacific
  • Fig. 106 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Japan Key Country Dynamics
  • Fig. 108 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 109 China Key Country Dynamics
  • Fig. 110 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 111 India Key Country Dynamics
  • Fig. 112 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 113 Australia Key Country Dynamics
  • Fig. 114 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 115 Thailand Key Country Dynamics
  • Fig. 116 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 117 South Korea Key Country Dynamics
  • Fig. 118 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 119 Latin America
  • Fig. 120 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 121 Brazil Key Country Dynamics
  • Fig. 122 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 123 Argentina Key Country Dynamics
  • Fig. 124 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 125 MEA
  • Fig. 126 MEA Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 127 South Africa Key Country Dynamics
  • Fig. 128 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 129 Saudi Arabia Key Country Dynamics
  • Fig. 130 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 UAE Key Country Dynamics
  • Fig. 132 UAE Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Kuwait Key Country Dynamics
  • Fig. 134 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 135 Strategy Mapping